Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Cytosorbents (CTSO) Accumulated Depreciation & Amortization (2016 - 2025)

Cytosorbents (CTSO) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $3.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Accumulated Depreciation & Amortization rose 60.07% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2023, up 60.07%, and an annual FY2023 reading of $3.0 million, up 60.07% over the prior year.
  • Accumulated Depreciation & Amortization was $3.0 million for Q4 2023 at Cytosorbents, up from $1.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $4.8 million in Q4 2021 and bottomed at $1.9 million in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.5 million, with a median of $3.7 million recorded in 2019.
  • The sharpest move saw Accumulated Depreciation & Amortization crashed 60.16% in 2022, then soared 60.07% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.7 million in 2019, then grew by 16.16% to $4.3 million in 2020, then increased by 11.99% to $4.8 million in 2021, then plummeted by 60.16% to $1.9 million in 2022, then skyrocketed by 60.07% to $3.0 million in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for CTSO at $3.0 million in Q4 2023, $1.9 million in Q4 2022, and $4.8 million in Q4 2021.